Literature DB >> 1671042

The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.

J R Zabrecky1, T Lam, S J McKenzie, W Carney.   

Abstract

The human breast carcinoma cell line SK-BR-3, expresses the neu oncogene product, p185, which is a receptor tyrosine kinase. Using a double monoclonal antibody capture enzyme-linked immunosorbent assay for p185, activity was detected in conditioned media from cultures of SK-BR-3 cells. Two monoclonal antibodies specific for the extracellular domain of p185/neu immunoprecipitated a protein with a molecular mass of approximately 105 kDa. p105 was further shown to compete with p185 for binding to monoclonal antibodies and pulse-chase experiments indicate that it was generated by post-translational processing. Peptide maps showed that p105 and p185 are related polypeptides. Since p105 is close to the predicted size for the extracellular domain of p185/neu, we propose that SK-BR-3 cells specifically process and release this portion of the receptor into the medium. The release of the extracellular domain may have implications in oncogenesis and its detection could prove useful as a cancer diagnostic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671042

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Authors:  A Esparís-Ogando; E Díaz-Rodríguez; A Pandiella
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Primary trastuzumab resistance: new tricks for an old drug.

Authors:  Jason A Wilken; Nita J Maihle
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

Review 3.  Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.

Authors:  Michael Hubalek; Christine Brunner; Karin Matthä; Christian Marth
Journal:  Wien Med Wochenschr       Date:  2010-10-26

4.  C-terminal truncated forms of Met, the hepatocyte growth factor receptor.

Authors:  M Prat; T Crepaldi; L Gandino; S Giordano; P Longati; P Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

Review 5.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

6.  Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Authors:  Wenle Xia; Zuguo Liu; Rongrong Zong; Leihua Liu; Sumin Zhao; Sarah S Bacus; Yubin Mao; Jia He; Julia D Wulfkuhle; Emanuel F Petricoin; Takuya Osada; Xiao-Yi Yang; Zachary C Hartman; Timothy M Clay; Kimberly L Blackwell; Herbert K Lyerly; Neil L Spector
Journal:  Mol Cancer Ther       Date:  2011-06-14       Impact factor: 6.261

7.  Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.

Authors:  Sun-Young Kong; Do Hoon Lee; Eun Sook Lee; Susan Park; Keun Seok Lee; Jungsil Ro
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

8.  Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.

Authors:  Sasha Gulati; Borgny Ytterhus; Unn S Granli; Michel Gulati; Stian Lydersen; Sverre H Torp
Journal:  Diagn Pathol       Date:  2010-03-23       Impact factor: 2.644

9.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

10.  Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.

Authors:  Patricia Diana Sørensen; Erik Hugger Jakobsen; Jonna Skov Madsen; Eva Brix Petersen; Rikke Fredslund Andersen; Birthe Østergaard; Ivan Brandslund
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.